To analyze whether CD4, CD25, Foxp3, IL-10, and TGF-β expression in CRC may be associated with clinical tumor progression we investigated tumors of limited disease (UICC I/II) and advanced disease (UICC III/IV). This evidence concerns the gene FOXP3 and neoplasm.